Bio-Rad Laboratories (NYSE:BIO – Get Free Report) will be releasing its earnings data after the market closes on Tuesday, May 7th. Analysts expect Bio-Rad Laboratories to post earnings of $2.04 per share for the quarter. Investors that are interested in registering for the company’s conference call can do so using this link.
Bio-Rad Laboratories (NYSE:BIO – Get Free Report) last released its earnings results on Thursday, February 15th. The medical research company reported $3.10 EPS for the quarter, beating the consensus estimate of $2.93 by $0.17. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 23.86%. The company had revenue of $681.18 million during the quarter, compared to analysts’ expectations of $685.00 million. During the same period last year, the firm earned $3.31 EPS. The business’s revenue for the quarter was down 6.7% on a year-over-year basis. On average, analysts expect Bio-Rad Laboratories to post $10 EPS for the current fiscal year and $11 EPS for the next fiscal year.
Bio-Rad Laboratories Trading Up 0.2 %
Shares of BIO opened at $279.83 on Monday. The stock’s fifty day simple moving average is $318.52 and its 200-day simple moving average is $314.71. The firm has a market capitalization of $7.98 billion, a PE ratio of -13.02 and a beta of 0.94. Bio-Rad Laboratories has a 12-month low of $261.59 and a 12-month high of $468.45. The company has a quick ratio of 4.34, a current ratio of 5.83 and a debt-to-equity ratio of 0.14.
Analyst Ratings Changes
Insider Activity
In other news, EVP Michael Crowley sold 3,000 shares of the company’s stock in a transaction dated Tuesday, February 27th. The stock was sold at an average price of $336.00, for a total value of $1,008,000.00. Following the completion of the sale, the executive vice president now directly owns 6,942 shares of the company’s stock, valued at approximately $2,332,512. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 17.06% of the stock is currently owned by company insiders.
About Bio-Rad Laboratories
Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.
Further Reading
- Five stocks we like better than Bio-Rad Laboratories
- What Are the FAANG Stocks and Are They Good Investments?
- MarketBeat Week in Review – 4/29 – 5/3
- 5 Top Rated Dividend Stocks to Consider
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- Golden Cross Stocks: Pattern, Examples and Charts
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.